Showing 1 - 20 of 53 Items
Showing 1 - 20 of 53 Items
Sort By: Relevance
Journal Article
|Research
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
BACKGROUND
Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...
Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...
Journal Article
|Short Report
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...
Journal Article
|Research
2023-11-01 • Bulletin of the World Health Organization
2023-11-01 • Bulletin of the World Health Organization
The World Health Organization has developed target product profiles containing minimum and optimum targets for key characteristics for tests for tuberculosis treatment monitoring and opt...
Journal Article
|Commentary
2023-09-11 • Lancet Child and Adolescent Health
2023-09-11 • Lancet Child and Adolescent Health
Journal Article
|Research
Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Journal Article
|Research
2023-06-01 • International Journal of Tuberculosis and Lung Disease
2023-06-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.
OB...
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.
OB...
Journal Article
|Research
2023-04-28 • PLOS Global Public Health
2023-04-28 • PLOS Global Public Health
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb tr...
Journal Article
|Letter
2023-04-01 • Lancet Global Health
2023-04-01 • Lancet Global Health
Journal Article
|Research
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Journal Article
|Research
2023-01-01 • Lancet Global Health
2023-01-01 • Lancet Global Health
BACKGROUND
Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control. We aimed to compare the diagnost...
Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control. We aimed to compare the diagnost...
Journal Article
|Research
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Journal Article
|Research
2022-09-15 • Clinical Infectious Diseases
2022-09-15 • Clinical Infectious Diseases
RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.
OBJECTIVES
Evaluate safety of longer MDR/RR-TB...
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.
OBJECTIVES
Evaluate safety of longer MDR/RR-TB...
Journal Article
|Letter
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|Short Report
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...
Conference Material
|Video
2019-06-13 • Epicentre Scientific Day 2019
2019-06-13 • Epicentre Scientific Day 2019
Journal Article
|Research
2022-05-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2022-05-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
BACKGROUND
The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).
OBJECTIVES
We assess...
The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).
OBJECTIVES
We assess...
Journal Article
|Research
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Journal Article
|Commentary
2021-02-12 • Lancet Infectious Diseases
2021-02-12 • Lancet Infectious Diseases
We are not alone in welcoming the study by Kelly E Dooley and colleagues 1 that sheds light on the QT prolonging effects of the combination of bedaquiline and delamanid, two key drugs fo...
Journal Article
|Commentary
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...
Journal Article
|Research
2010-12-01 • International Journal of Tuberculosis and Lung Disease
2010-12-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Although tuberculosis (TB) is a curable disease, it remains a major global health problem and an important cause of morbidity and mortality among vulnerable populations, incl...
Although tuberculosis (TB) is a curable disease, it remains a major global health problem and an important cause of morbidity and mortality among vulnerable populations, incl...